820 related articles for article (PubMed ID: 29695749)
1. Oncolytic viruses as engineering platforms for combination immunotherapy.
Twumasi-Boateng K; Pettigrew JL; Kwok YYE; Bell JC; Nelson BH
Nat Rev Cancer; 2018 Jul; 18(7):419-432. PubMed ID: 29695749
[TBL] [Abstract][Full Text] [Related]
2. Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy.
Rojas JJ; Sampath P; Hou W; Thorne SH
Clin Cancer Res; 2015 Dec; 21(24):5543-51. PubMed ID: 26187615
[TBL] [Abstract][Full Text] [Related]
3. Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment.
Shi T; Song X; Wang Y; Liu F; Wei J
Front Immunol; 2020; 11():683. PubMed ID: 32411132
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic Viruses: Priming Time for Cancer Immunotherapy.
Russell L; Peng KW; Russell SJ; Diaz RM
BioDrugs; 2019 Oct; 33(5):485-501. PubMed ID: 31321623
[TBL] [Abstract][Full Text] [Related]
5. Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors.
Rajani KR; Vile RG
Viruses; 2015 Nov; 7(11):5889-901. PubMed ID: 26580645
[TBL] [Abstract][Full Text] [Related]
6. Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines.
Vijayakumar G; McCroskery S; Palese P
J Virol; 2020 Jan; 94(3):. PubMed ID: 31694938
[TBL] [Abstract][Full Text] [Related]
7. Combining Tumor Vaccination and Oncolytic Viral Approaches with Checkpoint Inhibitors: Rationale, Pre-Clinical Experience, and Current Clinical Trials in Malignant Melanoma.
Cavalcante L; Chowdhary A; Sosman JA; Chandra S
Am J Clin Dermatol; 2018 Oct; 19(5):657-670. PubMed ID: 29961183
[TBL] [Abstract][Full Text] [Related]
8. Abscopal effects observed in cancer radiation therapy and oncolytic virotherapy: an overview.
Romano G; Marino IR
Drugs Today (Barc); 2019 Feb; 55(2):117-130. PubMed ID: 30816886
[TBL] [Abstract][Full Text] [Related]
9. Viro-immune therapy: A new strategy for treatment of pancreatic cancer.
Ibrahim AM; Wang YH
World J Gastroenterol; 2016 Jan; 22(2):748-63. PubMed ID: 26811622
[TBL] [Abstract][Full Text] [Related]
10. Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma.
Vijayakumar G; Palese P; Goff PH
EBioMedicine; 2019 Nov; 49():96-105. PubMed ID: 31676387
[TBL] [Abstract][Full Text] [Related]
11. Cancer immunotherapy: the beginning of the end of cancer?
Farkona S; Diamandis EP; Blasutig IM
BMC Med; 2016 May; 14():73. PubMed ID: 27151159
[TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint modulation: rational design of combination strategies.
Zamarin D; Postow MA
Pharmacol Ther; 2015 Jun; 150():23-32. PubMed ID: 25583297
[TBL] [Abstract][Full Text] [Related]
13. The expanding role of immunotherapy.
Martin-Liberal J; Ochoa de Olza M; Hierro C; Gros A; Rodon J; Tabernero J
Cancer Treat Rev; 2017 Mar; 54():74-86. PubMed ID: 28231560
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges.
Kyi C; Postow MA
Immunotherapy; 2016 Jun; 8(7):821-37. PubMed ID: 27349981
[TBL] [Abstract][Full Text] [Related]
15. Combination cancer immunotherapy and new immunomodulatory targets.
Mahoney KM; Rennert PD; Freeman GJ
Nat Rev Drug Discov; 2015 Aug; 14(8):561-84. PubMed ID: 26228759
[TBL] [Abstract][Full Text] [Related]
16. Potentiating prostate cancer immunotherapy with oncolytic viruses.
Lee P; Gujar S
Nat Rev Urol; 2018 Apr; 15(4):235-250. PubMed ID: 29434366
[TBL] [Abstract][Full Text] [Related]
17. Novel approaches in cancer immunotherapy -- a light at the end of the tunnel.
Joshi M; Pal SK; Drabick JJ
Discov Med; 2016 Jun; 21(118):479-87. PubMed ID: 27448784
[TBL] [Abstract][Full Text] [Related]
18. Combination immunotherapy of oncolytic virus nanovesicles and PD-1 blockade effectively enhances therapeutic effects and boosts antitumour immune response.
Ji W; Li L; Zhou S; Qiu L; Qian Z; Zhang H; Zhao P
J Drug Target; 2020 Nov; 28(9):982-990. PubMed ID: 32379004
[TBL] [Abstract][Full Text] [Related]
19. Arming oncolytic viruses to leverage antitumor immunity.
de Gruijl TD; Janssen AB; van Beusechem VW
Expert Opin Biol Ther; 2015 Jul; 15(7):959-71. PubMed ID: 25959450
[TBL] [Abstract][Full Text] [Related]
20. Integrating oncolytic viruses in combination cancer immunotherapy.
Bommareddy PK; Shettigar M; Kaufman HL
Nat Rev Immunol; 2018 Aug; 18(8):498-513. PubMed ID: 29743717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]